carmustine
Small molecule targets GSR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Carmustine medac (previously Carmustine Obvius) | — | 2018-07-18 | europa.eu ↗ |
| Label expansion | US (FDA) | GLIADEL | — | 2003-02-25 | fda.gov ↗ |
| Approved | US (FDA) | BICNU | — | 1977-03-07 | fda.gov ↗ |
Trials 143 · started per year
Also used as a comparator or background therapy in 103 trials
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 256 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carmustine | “Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day -19 and therapeutic...” PMID 23478060 ↗ Mar 2013209“Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous...” NCT02399189 ↗ “The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy...” NCT02099292 ↗ “A Single-center, Randomized Controlled Clinical Study of Zanubrutinib Combined With Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preconditioning Regimen for...” NCT06652165 ↗ “The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.” NCT01310868 ↗ “PURPOSE: To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma.” PMID 15234047 ↗ Jul 2004 “Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509 ↗ “Busulfan, carmustine and cyclophosphamide will be given to you for 5 days.” NCT05425654 ↗ “Drug: carmustine Given IV Other Names: BCNU BiCNU bis-chloronitrosourea” NCT05922384 ↗ “day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution” NCT01827605 ↗ “Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6” NCT02278796 ↗ “Chidemide，carmustine, etoposide, cytarabine, and melphalan” NCT05931263 ↗ “Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid;” NCT05075681 ↗ “surgery and carmustine wafers (CW), while deferring WBRT” PMID 24037801 ↗ Aug 2013 “VI-0609 (Carmustine with Propylene Glycol)” NCT06915246 ↗ “carmustine(BCNU)(250mg/m2/day, day -3)” NCT04582604 ↗ “Carfilzomib, Carmustine, Chlorambucil” NCT02788201 ↗ “Polifeprosan 20 with Carmustine 3.85%” NCT00919737 ↗ “BCNU(carmustine)on day -6 300mg/M2 IV” NCT00572013 ↗ “Day-3# Carmustine 250mg/m2/ day iv” NCT05088226 ↗ “carmustine 400 mg/m(2) i.v. Day -5” PMID 23242601 ↗ Dec 2012 “Carmustine\* 400 mg/m² i.v. (d-6)” NCT02531841 ↗ “Carmustine: 300 mg/m2 i.v. day 1” NCT00791947 ↗ “Carmustine 300mg/m², iv, day -7” NCT00946374 ↗ “Carmustine IV (100 mg/m²) day3” NCT00863460 ↗ “Carmustine: 300mg/m2 ivgtt D-8” NCT06652139 ↗ “Carmustine: 300mg/m2 ivgtt D-7” NCT05367856 ↗ “Carmustine 300mg/m\^2 IVD d-6” NCT03629873 ↗ “Gliadel wafer (carmustine)” NCT00362921 ↗ |
| Known as | 1,3-bis(2-chloroethyl)-1-nitrosourea | “To evaluate the toxic effects and maximum tolerated dose of topical carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea] following intravenous O6-benzylguanine in the treatment of...” PMID 22250189 ↗ May 2012 |
| Known as | BCNU | “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
* Carboplatin;
* Irinotecan;
* Etoposide;
*...” NCT03632135 ↗58“PURPOSE: This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in...” PMID 12721262 ↗ May 2003 “VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1...” NCT00461747 ↗ “We investigated the effect of stereotactic radiosurgery (SRS) added to conventional external beam radiation therapy (EBRT) with carmustine (BCNU) on the survival of patients with GBM.” PMID 15465203 ↗ Nov 2004 “The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.” NCT01310868 ↗ “Patients with supratentorial GBM were treated with a combination of carmustine (BCNU) and conformal irradiation (dose levels: 66, 72, 78, 84 Gy, respectively).” PMID 19533025 ↗ Jun 2009 “Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran” NCT00574509 ↗ “Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan.” NCT00281879 ↗ “two different high-dose methotrexate-based protocols followed by high-dose carmustine/thiotepa (BCNU/TT) plus ASCT” PMID 22473593 ↗ Apr 2012 “A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Metatstatic Melanoma” NCT00005961 ↗ “BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT” NCT02329080 ↗ “After the RT course, carmustine (BCNU) at 80 mg/m(2) was given for 3 days, every 8 weeks, for 6 cycles.” PMID 16750317 ↗ Jun 2006 “either erlotinib or a control arm that received treatment with either temozolomide or carmustine (BCNU)” PMID 19204207 ↗ Feb 2009 “BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab” NCT01468311 ↗ “BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)” NCT01500161 ↗ “high-dose Thiotepa-BCNU supported by autologous stem cell transplant” NCT00801216 ↗ “BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy” PMID 25407559 ↗ Nov 2014 “Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6” NCT02278796 ↗ “carmustine (BCNU), etoposide, cytarabine, melphalan” NCT07199296 ↗ “VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1” NCT00560053 ↗ “BEAM (BCNU, Etoposide, Cytarabine, Melphalan)” NCT02858258 ↗ “carmustine(BCNU) (250mg/m2/day, day -3)” NCT05075681 ↗ “Carmustine(BCNU) (250mg/m2/day, day -3)” NCT05088226 ↗ “carmustine(BCNU)(250mg/m2/day, day -3)” NCT04582604 ↗ “BCNU, Etoposide, Cytarabine, Melphalan” NCT03113162 ↗ “BCNU (carmustine): 300 mg/m²on day -5” NCT00571493 ↗ “BCNU(carmustine)on day -6 300mg/M2 IV” NCT00572013 ↗ “Carmustine, BCNU, NSC-409962.” NCT00002620 ↗ “BCNU Carmustine, NSC-409962” NCT00002599 ↗ “BCNU 300 mg/m2，ivgtt，d-6” NCT05814718 ↗ “BCNU 300mg/m2 on day -4” NCT00670631 ↗ “Carmustine (BCNU)” NCT00005637 ↗ “Carmustine (BCNU)” NCT00068952 ↗ “Carmustine BCNU” NCT00556127 ↗ “BCNU on dd 1” NCT01516593 ↗ “BCNU” NCT01637753 ↗ |
| Known as | Becenun | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | BiCNU | “BiCNU (Carmustine with Ethanol)” NCT06915246 ↗ |
| Known as | Bis-Chloroethyl-Nitroso-Urea | “Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide” NCT04755023 ↗ |
| Known as | Camustine | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | Carmubris | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | Carmustin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00647049 ↗ |
| Known as | Carmustina | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | Carmustine medac (previously carmustine obvius) | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | Carmustine obvius | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | CASANT | “The product in this study, Carmustine Sustained Release Implant (CASANT), is similar to that of Gliadel wafer as for the API(Active Pharmaceutical Ingredient), but different as...” NCT01656980 ↗ |
| Known as | DTI-015 | “Patients receive neoadjuvant carmustine in ethanol (DTI-015) intratumorally under stereotactic guidance 45-90 minutes prior to craniotomy and tumor resection.” NCT00009854 ↗2“Patients receive carmustine in ethanol (DTI-015) intratumorally over 5 minutes during stereotactic biopsy or open craniotomy.” NCT00006656 ↗ |
| Known as | FDA-0345 | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | Gliadel | “The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.” NCT01310868 ↗3“At the time of surgery, patients receive up to 8 polifeprosan 20 wafers with carmustine (Gliadel) implanted into the resection cavity.” NCT00045721 ↗ |
| Known as | Gliadel (carmustine wafers) | “Gliadel (carmustine wafers)” NCT01186406 ↗ |
| Known as | Gliadel wafer (carmustine) | “Gliadel wafer (carmustine)” NCT00362921 ↗ |
| Known as | Gliadel wafers | “Patients undergo surgical resection and receive up to 8 polifeprosan 20 with carmustine implants (Gliadel wafers) in the resected tumor cavity.” NCT00004892 ↗1“polifeprosan 20 with carmustine implant (Gliadel wafers)” NCT00003878 ↗ |
| Known as | NSC-409962 | “Carmustine, BCNU, NSC-409962.” NCT00002620 ↗1“BCNU Carmustine, NSC-409962” NCT00002599 ↗ |
| Known as | SK-27702 | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | SRI-1720 | ChEMBL registry synonym — accepted as the source's own label CHEMBL513 ↗ |
| Known as | VI-0609 | “VI-0609 (Carmustine with Propylene Glycol)” NCT06915246 ↗ |
| Action | Inhibit | “Glutathione reductase inhibitor” CHEMBL513 ↗ |
| Modality | Small molecule | “Carmustine is an alkylating agent.” NCT03072771 ↗ |
| Route | Intravenous | “Patients without extensive prior radiotherapy undergo radiotherapy to areas of measurable active disease plus a 2 cm margin on days -21 to -17 and -14 to -8. Patients without a...” NCT00002461 ↗ |
| Target | GSR | “Glutathione reductase inhibitor” CHEMBL513 ↗ |